Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors

Kidney International

Volumn 67, Issue 5, 2005, Pages 1672-1676

  Urbich, Carmen ^a   Dimmeler, Stefanie ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLINOSITOL KINASE; PROTEIN KINASE B; VASCULOTROPIN;

ANGIOGENESIS; BONE MARROW; CARDIOVASCULAR RISK; CD34 SELECTION; CELL ISOLATION; CELL REGENERATION; CONFERENCE PAPER; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENDOTHELIUM CELL; HEART INFARCTION; HEMATOPOIETIC STEM CELL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MONONUCLEAR CELL; PRIORITY JOURNAL; STEM CELL;

EID: 17744388581     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.00261.x     Document Type: Conference Paper

References (50)

1. CARMELIET P: Mechanisms of angiogenesis and arteriogenesis. Nat Med 6:389-395, 2000
2. ASAHARA T, et al: Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221-228, 1999
3. TAKAHASHI T, et al: Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5:434-438, 1999
4. KALKA C, et al: Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 97:3422-3427, 2000
5. ASSMUS B, et al: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 106:3009-3017, 2002
6. ASAHARA T, et al: Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964-967, 1997
7. SHI Q, et al: Evidence for circulating bone marrow-derived endothelial cells. Blood 92:362-367, 1998
8. GEHLING UM, et al: In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 95:3106-3112, 2000
9. FERNANDEZ PUJOL B, et al: Endothelial-like cells derived from human CD14 positive monocytes. Differentiation 65:287-300, 2000
10. DIMMELER S, et al: HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108:391-397, 2001
11. HEISSIG B, et al: Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 109:625-637, 2002
12. VASA M, et al: Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89:E1-E7, 2001
13. MUROHARA T, et al: Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization. J Clin Invest 105:1527-1536, 2000
14. KAWAMOTO A, et al: Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103:634-637, 2001
15. URBICH C, et al: Relevance of monocytic features for neovascularization capacity of circulating endothelial progenitor cells. Circulation 108:2511-2516, 2003
16. KOCHER AA, et al: Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7:430-436, 2001
17. TATEISHI-YUYAMA E, et al: Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360:427-435, 2002
18. DIMMELER S, HAENDELER J, ZEIHER AM: Regulation of endothelial cell apoptosis in atherothrombosis. Curr Opin Lipid 13:531-536, 2002
19. ROSSIG L, DIMMELER S, ZEIHER AM: Apoptosis in the vascular wall and atherosclerosis. Basic Res Cardiol 96:11-22, 2001
20. TEDGUI A, MALLAT Z: Apoptosis as a determinant of atherothrombosis. Thromb Haemost 86:420-426, 2001
21. PEICHEV M, et al: Expression of VEGFR-2 and AC133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood 95:952-958, 2000
22. DIMMELER S, ZEIHER AM: Vascular repair by circulating endothelial progenitor cells: The missing link in atherosclerosis? J Mol Med 20:20, 2004
23. HRISTOV M, ERL W, LINDER S, WEBER PC: Apoptotic bodies from endothelial cells enhance the number and initiate the differentiation of human endothelial progenitor cells in vitro. Blood 8:8, 2004
24. HU Y, DAVISON F, ZHANG Z, XU Q: Endothelial replacement and angiogenesis in arteriosclerotic lesions of allografts are contributed by circulating progenitor cells. Circulation 108:3122-3127, 2003
25. SILVESTRE JS, et al: Transplantation of bone marrow-derived mononuclear cells in ischemic apolipoprotein E-knockout mice accelerates atherosclerosis without altering plaque composition. Circulation 108:2839-2842, 2003
26. SCHATTEMAN GC, HANLON HD, JIAO C, et al: Blood-derived angioblasts accelerate blood-flow restoration in diabetic mice. J Clin Invest 106:571-578, 2000
27. LOOMANS CJ, et al: Endothelial progenitor cell dysfunction: A novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53:195-199, 2004
28. TEPPER OM, et al: Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures. Circulation 106:2781-2786, 2002
29. VERMA S, et al: C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: Further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109:2058-2067, 2004
30. HILL JM, et al: Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348:593-600, 2003
31. LAMBIASE PD, et al: Circulating humoral factors and endothelial progenitor cells in patients with differing coronary collateral support. Circulation 109:2986-2992, 2004
32. ASAHARA T, et al: VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. Embo J 18:3964-3972, 1999
33. STREHLOW K, et al: Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107:3059-3065, 2003
34. HEESCHEN C, et al: Erythropoietin is a potent physiological stimulus for endothelial progenitor cell mobilization. Blood 17:17, 2003
35. LAUFS U, et al: Physical training increases endothelial progenitor cells, inhibits neointima formation, and enhances angiogenesis. Circulation 22:22, 2003
36. LLEVADOT J, et al: HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108:399-405, 2001
37. VASA M, et al: Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 103:2885-2890, 2001
38. WALTER DH, et al: Statin therapy accelerates reendothelialization: A novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105:3017-3024, 2002
39. WERNER N, et al: Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: Effect of 3-hydroxy-3- methylglutaryl coenzyme a reductase inhibition. Arterioscler Thromb Vasc Biol 22:1567-1572, 2002
40. LANDMESSER U, et al: Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 20:20, 2004
41. LAUFS U, LIAO JK: Targeting Rho in cardiovascular disease. Circ Res 87:526-528, 2000
42. ASSMUS B, et al: HMG-CoA reductase inhibitors reduce senescence and increase proliferation of endothelial progenitor cells via regulation of cell cycle regulatory genes. Circ Res 3:3, 2003
43. AICHER A, et al: Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9:1370-1376, 2003
44. SPYRIDOPOULOS I, et al: Stalins enhance migratory capacity by upregulation of the telomere-capping protein TRF2 in endothelial progenitor cells. Circulation 2004 (in press)
45. KUREISHI Y, et al: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004-1010, 2000
46. DIMMELER S, ASSMUS B, HERMANN C, et al: Fluid shear stress stimulates phosphorylation of Akt in human endothelial cells: Involvement in suppression of apoptosis. Circ Res 83:334-342, 1998
47. DIMMELER S, et al: Activation of nitric oxide synthase in endothelial cells via Akt-dependent phosphorylation. Nature 399:601-605, 1999
48. BAO H, et al: Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SREI cells). Blood 93:3757-3773, 1999
49. SIMONCINI T, et al: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 407:538-541, 2000
50. GERBER HP, et al: Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273:30336-30343, 1998